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Tyrosine phosphorylation and 
dephosphorylation 
Tyrosine phosphorylation is a key mechanism for 
signal transduction and for the regulation of many 
cellular processes (Mustelin et al., 2005; Tonks, 2006). 
The protein tyrosine kinases (PTKs) phosphorylate at 
tyrosine residues and the protein tyrosine phosphatases 
(PTPs) dephosphorylate. The human PTP genes are 
divided into several families: Class I cysteine-based 
PTPs, class II cysteine-based PTPs, class III cysteine-
based PTPs and Asp-based PTPs (Andersen et al., 
2004; Mustelin et al., 2005). The class I cysteine-based 
family constitute the largest family of PTPs, and is 
further classified into 38 classical PTPs and 61 VH1-
like "dual-specific" protein phosphatases (DSPs) 
(Alonso et al., 2004). Of the 38 classical PTPS, 17 are 
non-receptor intracellular PTPs and 21 are receptor-like 
transmembrane PTPs. All the classical PTPs are strictly 
tyrosine-specific (pTyr). In contrast, the VH1-like 
DSPs are much more diverse and are divided into 
several subgroups: PTPs specific for mitogen-activated 
protein (MAP)-kinases (MKPs), atypical DSPs 
including VHR, VHY, VHX and VHZ, slingshots, 
PRLs, CDC14s, PTENs and myotubularins (Alonso et 
al., 2004).  
PTPs have a catalytic domain with an intrinsic substrate 
preference, and most have non-catalytic amino- or 
carboxy terminal extensions domains that interact with
other molecules or targets (Mustelin et al., 2005). The 
non-catalytic regions can also participate in regulation  
of phosphatase activity by intramolecular folding 
mechanisms (Mustelin et al., 2005). It has been long 
appreciated that PTPs have capacity to function as 
inhibitors by phosphotyrosine (pTyr)-dependent 
signaling, but also to act as positive regulators in 
promoting signaling (Mustelin et al., 1999; Gjörloff 
Wingren et al., 2000; Andersen et al., 2004; Mustelin t 
al., 2005; Tonks, 2006). Lymphocytes express 50-60 of 
the total 107 PTP genes. The most well-studied PTPs in 
lymphocytes are presented in Table 1 (12 non-receptor 
intracellular PTPs, PTEN and the class II cysteine-
based PTP LMW-PTP). 
Lymphoma and leukemia 
Tumors of the immune system are classified as either 
leukemia or lymphoma. Leukemias often proliferate as 
single cells in the blood or lymph while lymphomas 
tend to proliferate as solid tumors within lymphoid 
tissues. Historically, the lymphomas have been 
classified as either Hodgkin's lymphoma (HL) or non-
Hodgkin's lymphoma (NHL), the latter diagnosis being 
the most common and comprising many different 
subtypes originating from B-cells, T-cells or naturl 
killer (NK) cells. About 85 % of the NHLs are of B-cell 
origin and these B-cell lymphomas can be divided into
around 15 types according to the World Health 
Organization (WHO) lymphoma classification (Jaffe et 
al., 2001; Swerdlow et al., 2008). The various subtypes 
can have very different clinical behaviours and 
requirements for treatment strategies, due to the 
differentiation stage of the B-cell they originated from. 
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Table 1. Commonly studied PTP genes in the human genome. 
 
As the different stages of B-cell development and 
maturation are characterized by the structure of the 
BCR and of the expression of certain differentiation 
markers, and since the malignant B-cell is said to be 
"frozen" at the particular stage it developed from, this 
can be used to determine the cellular origin of the B-
cell lymphoma. Diffuse large B-cell lymphoma 
(DLBCL) is together with B-cell chronic lymphocytic 
leukemia (CLL), mantle cell lymphoma and follicular 
lymphoma the most common B-cell lymphomas in 
adults. DLBCLs exhibit marked biological 
heterogeneity and variable clinical presentation and 
clinical course. DLBCL and Burkitt lymphoma (BL) 
account for the majority of aggressive lymphomas in 
adults and children. Conversely, BL is genetically 
relatively homogeneous but associated with variable 
clinicopathological features (de Leval and Hasserjian, 
2009). Gene expression profiling is a powerful tool to 
uncover complex molecular networks in cancer and, 
specifically, in malignant lymphomas. Within DLBCL, 
germinal center B-cell-like (GCB) DLBCL, strongly 
resembles normal germinal center B-cells and has a 
good prognosis following chemotherapy, whereas 
activated B-cell-like (ABC) DLBCL resembles 
mitogenically activated blood B cells and has a poor 
outcome (Shipp et al., 2002; Rosenwald et al., 2002). 
Gene expression profiling furthermore allows the 
molecular separation of BL from DLBCL and reveals a 
Burkitt-specific signature which is also expressed by a 
subset of tumors that are currently classified as 
DLBCL. 
B-cells are especially vulnerable for transforming 
events during the rearrangements of their BCR, hence 
the over representation of B-cell lymphomas derived 
from the GC compartment where somatic 
hypermutation takes place. Many B-cell leukemias and
lymphomas involve an oncogene (mutated and 
proliferation-enhancing version of a normal gene) that 
has developed from the corresponding proto-oncogene 
(normal version of the oncogene) translocated into the 
Ig-genes. As a consequence, the oncogene is controlled 
by the Ig-locus and this result in a deregulated, 
constantly expressed oncogene, contributing to the 
lymphoma pathogenesis. 
Protein tyrosine kinases 
PTKs of the SRC (from "neoplastic transformation of 
cell by avian sarcoma virus is mediated by a single 
viral gene (src)", one of the most extensively studied 
retroviral oncogenes), SYK (Spleen tyrosine kinase), 
TEC (Tec protein tyrosine kinase) and CSK (c-terminal 
src tyrosine kinase) families are crucial for antigen-
receptor induced lymphocyte activation (Ku et al., 
1994; Sato et al., 1994; Coussens et al., 1985). LCK
(lymphocyte-specific protein tyrosine kinase) (Marth et 
al., 1985), and the proto-oncogene protein tyrosine 
kinases FYN (FYN binding protein, FYB-120/130) 
(Alland et al., 1994; Resh, 1998) and YES (Semba et 
al., 1985)  
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Table 2. Commonly studied PTK genes in the human genome. 
 
are expressed in T cells, and LYN (tyrosine protein 
kinase Lyn) (Yamanashi et al., 1987), FYN and BLK 
(B lymphocyte kinase) (Dymecki et al., 1990) in B 
cells. The most well-studied PTKs in lymphocytes are
presented in Table 2. 
In haematopoietic cells, SRC kinases such as LCK, 
FYN and LYN are the first protein tyrosine kinases that 
are activated after stimulation through the 
immunoreceptors. They phosphorylate ITAMs 
(immunoreceptor tyrosine-based activation motifs) that 
are present in the signal transducing subunits of the 
immunoreceptors, thereby providing binding sites for 
SRC homology 2 (SH2)-domain containing molecules, 
such as SYK (Mustelin et al., 2005). The SYK-family 
kinases, SYK and ZAP70 (ζ-chain-associated protein 
kinase of 70 kDa) function downstream of the SRC-
family kinases to amplify the signal and are focal 
points for the assembly of signalling complexes (Chan 
et al., 1991; Bradshaw, 2010; Wang et al., 2010). Many 
PTKs, such as the SRC-family and SYK-family PTKs 
found in B and T cells, are tightly controlled by PTPs. 
ZAP70 plays a critical role in the events involved in 
initiating T cell responses by the antigen receptor 
(Wang et al., 2010). The importance of functional 
ZAP70 has been revealed by observations of both 
Zap70 deficient humans and mice. ZAP70 deficient 
patients have no functional T cells in their peripheral 
blood and suffer from severe combined 
immunodeficiency (SCID) (Wang et al., 2010). Apart 
from the critical role in T cells, ZAP70 is also 
expressed in some populations of activated B cells and 
in B cell CLL (B-CLL) (Chen et al., 2007; Gobessi et 
al., 2007; Chen et al., 2008). B-CLL causes 
accumulation of monoclonal CD5+ B cells in the 
blood, bone marrow, lymph nodes and spleen. Several 
different prognostic factors have been proposed for 
patients with B-CLL. In around 50% of patients with 
B-CLL, the immunoglobulin heavy-chain variable-
region (IgVH) genes have undergone somatic 
mutations which can be identified by sequencing these 
genes. It has been shown that patients whose B-CLL 
cells express mutated Ig genes have a better prognosis 
than patients whose B-CLL cells express unmutated Ig 
genes (100% germline Ig identity) (Hallek et al., 2008). 
It has been shown that ZAP-70 is the most promising 
candidate marker to replace the need for IgVH studying 
for mutational status with a high predictive value 
(Chen, 2002). The role of ZAP70 in a B cell disease is 
unclear. B cells normally express PTK Syk instead of 
ZAP70. Syk and ZAP70 function downstream of Src-
family kinases, which are PTKs such as Lck, Fyn and
Lyn and the first tyrosine kinases to be activated after 
stimulation through the immunoreceptors (Mustelin et 
al., 2005). The phosphorylation of their targets provide 
binding sites for Syk and Zap70. As B-CLL cells are 
characterized by lower surface expression of IgM and
CD79b than normal B lymphocytes, it is conceivable 
that association between ZAP-70 and CD79b may 
facilitate the recruitment of a Src kinase such as Lyn to 
the BCR complex, resulting in Lyn-mediated 
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phosphorylation of the limiting numbers of ITAMs of
CD79b following BCR ligation. Regardless of how 
ZAP-70 promotes BCR signaling in B-CLL, it is clear 
that its expression is associated with a worse prognosis. 
Expression of ZAP-70 is now being used clinically for
prognostication. 
Protein tyrosine phosphatases 
PTPN6 or SHP-1 (SH2-domain-containing 
phosphatase-1) is a cytosolic key regulatory PTP that 
controls intracellular phosphotyrosine levels 
predominantly in hematopoietic cells of all lineages, 
but is also expressed at lower levels in epithelial cel s 
(Lorenz, 2009). The human SHP-1 gene is located on 
chromosome 12p13 (Plutzky et al., 1992; Matsushita et 
al., 1999). It consists of 17 exons and spans 
approximately 17 kb of DNA with a transcription size 
of 2,4-2,6 kb (Wu et al., 2003). The SHP-1 gene 
encodes two forms of SHP-1 protein, with differences 
in the N-terminal, but with negligible activity as a 
result. Two different and mutually exclusive tissue-
specific promoters regulate expression of the two forms 
of SHP-1 protein. Promoter 1 is active in all cells of 
non-hematopoietic origin, whereas promoter 2 is active 
exclusively in cells of hematopoietic lineage (Wu et al., 
2003). Structurally, both SHP-1 and SHP-2 are 
composed of a central catalytic domain containing a 
specific PTP signature motif, two SH2 domains at their 
N-termini and a C-terminus (Poole and Jones, 2005). 
The SH2 domains are important for localization and 
activity regulation (Lorenz, 2009). The N-terminal SH2 
domain is intramolecularly associated with the PTP 
domain, thereby repressing its activity. The repression 
is released when the SH2 domains are engaged, leading 
to activation of the phosphatase. Two tyrosines in the 
C-termini of SHP-1 (Y536 and Y564) and SHP-2 
(Y542 and Y580) have been shown to become 
phosphorylated upon various stimuli which further 
influence the function and activities. Importantly, SHP-
1 has also been proposed to have a role as a tumour-
suppressor in lymphoma and leukaemia since decreased 
levels of both SHP-1 protein and mRNA have been 
observed in these malignancies (Wu et al., 2003). 
Moreover, SHP1 may be involved in the clinical 
evolution of myelodysplastic syndrome (MDS) (Mena-
Duran, 2005). The role of SHP-1 in acute 
lymphoblastic leukaemia (ALL) has also been 
investigated, revealing that both SHP-1 and the tumor 
suppressor PTEN showed a significant difference in 
expression compared to nonmalignant controls 
(Gauffin et al., 2009). Studies also show that activ ted 
proliferation of B-cell lymphomas/leukemias with 
SHP1 gene silencing by aberrant CpG methylation 
(Koyama et al., 2003; Sato et al., 2010). 
SHP-1 has been proposed as a candidate tumor 
suppressor gene since a decreased expression level of  
SHP-1 has been reported in several different types of 
haematological malignancies (Wu et al., 2003). Several  
mechanisms have been suggested for low expression 
level of SHP-1 protein and also SHP-1 mRNA in these 
malignancies: methylation of the promoter region of 
the SHP-1 gene or the post-transcriptional block of 
SHP-1 and also mutation of the SHP-1 gene.  
Taken together, SHP-1 protein has a central role in 
normal cell growth by regulating the activity of protein 
tyrosine kinases. Since the negative regulatory functio  
of SHP-1 and its central role in many hematological 
malignancies has been suggested, it has been of great 
interest to find which molecules or substrates interact 
with SHP-1 protein. In this context, several different 
putative substrates for SHP-1 have been proposed. For 
instance, ZAP-70 and Syk have been proposed as 
potential substrates for SHP-1 in intact cells 
(Brockdorff et al., 1999). 
Several other PTPs have been identified as the products 
of tumor suppressor genes (Tonks, 2006). One of the 
most studied is the PTP tumor suppressor, PTEN, a 
dual-specificity phosphatase, which is selective for
dephosphorylating the critical phosphothreonine and 
phosphotyrosine residues. PTEN is short for 
"Phosphatase and tensin homologue deleted on 
chromosome 10", also referred to as "mutated in 
multiple advanced cancers" (MMAC1), and was 
discovered in 1997 (Li et al., 1997; Steck et al., 1997). 
PTEN is frequently inactivated in somatic cancers and
is ranked the second most mutated tumour suppressor 
gene after p53 (Di Cristofano and Pandolfi, 2000; 
Georgescu, 2010). Loss of PTEN is seen in over half of 
all glioblastomata and in a high portion of breast nd 
prostate cancer, in lymphomas and many other 
common malignancies (Tautz et al., 2009). 
SHP-2, which is encoded by the PTPN11 gene was the 
first PTP with proven oncogenic function (Östman et 
al., 2006; Tonks, 2006).  
Gain-of-function mutations in SHP-2, initially 
identified as Noonan syndrome, facilitate activation of 
the PTP (Tartaglia et al., 2001). SHP-2 normally 
facilitates Ras activation by regulating the activity of 
Src-family PTKs, or the level of Sprouty proteins 
(Östman et al., 2006). Activating somatic mutations in 
the gene PTPN11 have been associated with increased 
risk of certain sporadic childhood malignancies, such as 
juvenile myelomonocytic leukemia (JMML) and acute 
myeloid leukemia (AML), which induce 
hypersensitivity to granulocyte-macrophage colony-
stimulating factor (GM-CSF) in hematopoietic 
progenitor cells (Östman et al., 2006).  
Upon transplantation into lethally-irradiated mice, bone 
marrow expressing leukemia-associated SHP-2 mutants 
give rise to a fatal invasive myeloproliferative disease 
that is associated with hyperactivation of the mitogen-
activated protein kinase (MAPK) Erk and other 
signalling pathways (Mohi et al., 2005). The 
LEOPARD syndrome shares clinical features with the 
Noonan syndrome, but is instead associated with 
mutations that act as dominant negatives and interfere  
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with Erk MAPK activation (Kontaridis et al., 2006). 
Except for SHP-2, one more intracellular PTPs has 
been shown to have positive regulatory function, 
namely low molecular weight protein tyrosine 
phosphatases (LMW-PTP) (Mustelin et al., 2005). 
LMW-PTP dephosphorylates the negative regulatory 
site Y292 of PTK Zap70, which results in a slower 
down-modulation of cell surface T cell receptor (TCR) 
(Bottini et al., 2002a). Acid phosphatase locus 1 
(ACP1) is a polymorphic gene located on chromosome 
2 showing three common codominant alleles: ACP1A, 
ACP1B and ACP1C (Hopkinson et al., 1963; Bottini et 
al., 1995). The corresponding 6 genotypes are 
associated with different enzymatic activities (Spencer 
et al., 1964). The ACPs, or LMW-PTPs, are a group of 
tyrosine phosphatases expressed in certain tissue 
including glandular cells of different tissue as well as 
lymphocytes, breast, colon, brain, gastric ventricle and 
prostate. LMW-PTP has been characterized as tyrosine, 
but not a serine or threonine phosphatase (Malentacchi 
et al., 2005). In humans, LMW-PTP is expressed by a 
single copy gene located on chromosome 2. The 
primary transcript shows a complex pattern of 
alternative splicing which leads to the production f 
four different mRNAs. The role of LMW-PTP in cell 
proliferation seems to be important and is carried out 
by dephosphorylation leading to inactivation of 
tyrosine kinases such as the insulin-receptor, platelet- 
derived growth factor-receptor (PDGF-R), the ephrin 
receptor and docking proteins such as β-catenin having 
both adhesion and transcription activity (Chiarugi et al., 
2002; Chiarugi et al., 2004). The enzyme interacts wi h
several receptors and proteins and is involved in the 
regulation of Jak/STAT, which is one of the signalig 
pathways that is often dysregulated in leukemias. 
Moreover, the JAK-gene is linked to some 
hematopoietic malignancies. Inhibition of LMW-PTP 
results in a partly increased and prolonged 
phosphorylation of JAK/STAT as well as a decrease in 
apoptosis. Oxidation of the enzyme also leads to ani-
apoptotic effects. Over-expression of LMW-PTP has 
been shown to counteract malign transformation and 
signaling of tyrosine kinase oncogenes. Moreover, 
over-expression of LMW-PTP is also associated with 
several cancer forms (Bottini et al., 2002b; Alho et al., 
2008). 
Hematopoietic phosphatase (HePTP), PTPN7, is the 
only pTyr-specific PTP known to dephosphorylate 
MAPKs in hematopoietic cells (Saxena et al., 1999; 
Sergienko et al., 2012). HePTP is a 38-kDa enzyme, 
consisting of the C-terminal catalytic PTP domain and 
a short (45 residues) N-terminal extension, which 
contains the kinase interaction motif (KIM, residues 
15-31) (Zanke et al., 1992; Zanke et al., 1994; Adachi 
et al., 1994). The first indication of a role of HePTP in 
cell proliferation or differentiation came from the 
finding that the HePTP gene is located on the long arm
of chromosome 1, which is often found in extra copies  
(trisomy) in bone marrow cells from patients with 
MDS, which is characterized by reduced hematopoiesis 
and increased risk of acute leukemia. Indeed, 
amplification and overexpression of HePTP is also 
reported in cases of acute myeloid leukemia (AML) 
(Saxena et al., 1999). HePTP is down-regulated in 
pediatric lymphoma compared to control lymphoid 
cells (Fridberg et al., 2008). Loss of HePTP might 
indicate increased cell proliferation and/or survival of 
lymphoma cells. 
T-cell phosphatase (TC-PTP), PTPN2, (Mosinger et al., 
1992) is described as a phosphatase for both JAKs and 
STATs, which are important signaling proteins 
downstream of cytokine receptors (Kleppe et al., 2011). 
TC-PTP has been shown to be a tumor suppressor gene 
in T-cell malignancies (Kleppe, 2010; Kleppe, 2011). 
Moreover, TC-PTP was identified as a physiological 
regulator of STAT6 phosphorylation in ABC-like 
DLBCLs, which may contribute to the different 
biological characteristics of these DLBCL tumors (Lu 
et al., 2007). 
Summary and conclusion 
Many PTKs have already been discovered as drug 
targets and the treatment of many human diseases. Also 
PTPs will be found to be involved in human diseases 
and will be used as drug targets to treat these diseases 
in the future. However, there is a great need to 
investigate interactions between factors which are 
likely of pathogenic importance to develop new 
therapeutics for patients with lymphoma and/or 
leukemia. Moreover, establishing laboratory tests 
which are sufficiently sensitive and specific to be
prognostic for these patients might influence 
management decisions for determining the best course 
of treatment. 
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